A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Andecaliximab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
    • 19 Jan 2017 This trial has been completed in Belgium (end date: 16 Nov 2016).
    • 06 Oct 2016 This trial was completed in Spain, according to Eudra record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top